Ontology highlight
ABSTRACT: Background
The ideal oral anticoagulant agent during catheter ablation (CA) for atrial fibrillation (AF) remained unclear.Hypothesis
Novel oral anticoagulants (NOACs) are safer and effective compared to uninterrupted vitamin K antagonists (U-VKA) among patients requiring CA for AF.Methods
Four randomized controlled trials (RCTs) and 9 observational studies (OS) were selected using PubMed/Medline, EMBASE and the CENTRAL data bases (Inception-December-2017). Estimates were reported as random effects risk ratio (RR) with 95% confidence interval (CI). The primary safety outcome was major bleeding and main efficacy endpoint was thromboembolism.Results
In RCTs restricted analysis, NOACs significantly reduced the relative risk of major bleeding by 72% compared to U
SUBMITTER: Rahman H
PROVIDER: S-EPMC7453962 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature